Why EVQLV? The Interesting Story Behind Our Name

Feb 19, 2020 | Blog | 1 comment

Daniel Gigante

Andrew Satz (CEO) and I had a conversation covering a question we hear quite a bit: how did we come up with the name EVQLV? It’s an interesting story that includes evolution, amino acids and startups. Enjoy!

Transcript of Conversation

Daniel: Andrew, how did you come up with the name EVQLV?

Andrew: We started working on evolutionary algorithms in 2019, and we always thought about the fact we were building things around evolution. Obviously, if you look around the internet, the word “evolution” or “evolve.com” are taken as company names. As we were developing our work, and we’re in the antibody space, and antibodies are comprised of amino acids. There are 20 common amino acids and they’re each represented by a letter of the alphabet, and the first five letters on the heavy chain of the amino acid sequence are E-V-Q-L-V.  We were like, wow, that’s very cool! It looks like the word “evolve.”

Some other things, we want to change the way people see life sciences and pharmaceuticals. So, making the “O” a “Q” was a nod to that goal. Interestingly enough, when I thought about how the logo would look, I thought we should make the line coming out of the Q a double helix…when we tried to make it, it looked really weird. EVQLV [the name] is also very startupy. You know, companies use a 3 instead of a B or a 4 instead of an A…it was really all of those things coming together and we agreed: this is an awesome name.

1 Comment

  1. Anon

    Great post, very helpful!

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

The depth, vision and progress of EVQLV

Our CEO, Andrew Satz, recently spoke at Columbia University School of General Studies’ “Alumni in Action.” The subject of his talk was artificial intelligence. One of the questions posed to Andrew was what we were doing outside of coronavirus, along with the long term plans of our company

EVQLV Applies Proprietary AI Technology in Collaboration with Twist Bioscience to Discover and Validate Novel Antibody Therapies

EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.

EVQLV’s Evolutionary Algorithm Explained

Brett Averso (CTO, EVQLV) and Bhoomika Kumar (SciTech intern, EVQLV) teamed up to provide a high-level overview of how EVQLV’s evolutionary algorithm works.

Andrew Satz on the Talent Finders Podcast

EVQLV’s CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more.

Pin It on Pinterest